Affiliation:
1. Scripps Health San Deigo California USA
Abstract
AbstractImmunotherapy is an important modality in the treatment of many types of malignancy. The optimal duration of treatment with immunotherapy in patients with metastatic malignancies who experience complete responses is not fully understood. Our case demonstrates a protracted complete response in a patient with metastatic gastric adenocarcinoma after just three doses of pembrolizumab. This illustrates a need for further research into which patients might have responses such as these and could therefore be spared additional doses of an expensive treatment with many potential side effects.